NO20083576L - Peptider av regulatoriske eller hjelpeproteiner av HIV, samt sammensetninger og anvendelser derav - Google Patents

Peptider av regulatoriske eller hjelpeproteiner av HIV, samt sammensetninger og anvendelser derav

Info

Publication number: NO20083576L
Authority: NO; Norway
Prior art keywords: seq; polypeptide; hiv; regulatory; peptides
Prior art date: 2006-03-10

Application number

NO20083576A

Other languages

English (en)

Norwegian (no)

Inventor

Alan Gregory Stoloff

Romero Wilson Caparros-Wanderley

Original Assignee

Peptcell Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-03-10

Filing date

2008-08-18

Publication date

2008-12-10

2006-03-10 Priority claimed from GB0604920A external-priority patent/GB0604920D0/en

2006-07-18 Priority claimed from GB0614260A external-priority patent/GB0614260D0/en

2008-08-18 Application filed by Peptcell Ltd filed Critical Peptcell Ltd

2008-12-10 Publication of NO20083576L publication Critical patent/NO20083576L/no

Links

102000004196 processed proteins & peptides Human genes 0.000 title abstract 5
108090000765 processed proteins & peptides Proteins 0.000 title abstract 5
239000000203 mixture Substances 0.000 title 1
102000004169 proteins and genes Human genes 0.000 title 1
108090000623 proteins and genes Proteins 0.000 title 1
230000001105 regulatory effect Effects 0.000 title 1
229920001184 polypeptide Polymers 0.000 abstract 4
108700018351 Major Histocompatibility Complex Proteins 0.000 abstract 2
150000001413 amino acids Chemical class 0.000 abstract 2
230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 abstract 2
108700028369 Alleles Proteins 0.000 abstract 1
241000251539 Vertebrata <Metazoa> Species 0.000 abstract 1
108010067390 Viral Proteins Proteins 0.000 abstract 1
230000002163 immunogen Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
- C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
- C07K14/16—HIV-1 ; HIV-2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55544—Bacterial toxins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16071—Demonstrated in vivo effect
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Virology (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Genetics & Genomics (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Gastroenterology & Hepatology (AREA)
Microbiology (AREA)
Epidemiology (AREA)
Biophysics (AREA)
Mycology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Communicable Diseases (AREA)
Hematology (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
General Chemical & Material Sciences (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
AIDS & HIV (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Biomedical Technology (AREA)
Tropical Medicine & Parasitology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

NO20083576A 2006-03-10 2008-08-18 Peptider av regulatoriske eller hjelpeproteiner av HIV, samt sammensetninger og anvendelser derav NO20083576L (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB0604920A GB0604920D0 (en)	2006-03-10	2006-03-10	Peptide sequences and compositions
GB0614260A GB0614260D0 (en)	2006-07-18	2006-07-18	Peptide sequences and compositions
PCT/GB2007/000812 WO2007104932A2 (en)	2006-03-10	2007-03-09	Peptides of regulatory or accessory proteins of hiv, compositions and the utilization thereof

Publications (1)

Publication Number	Publication Date
NO20083576L true NO20083576L (no)	2008-12-10

Family

ID=38232608

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20083576A NO20083576L (no)	2006-03-10	2008-08-18	Peptider av regulatoriske eller hjelpeproteiner av HIV, samt sammensetninger og anvendelser derav

Country Status (20)

Country	Link
US (4)	US20100055119A1 (pt)
EP (2)	EP2392587B1 (pt)
JP (3)	JP2009529570A (pt)
KR (1)	KR20080106467A (pt)
CN (2)	CN102443052B (pt)
AP (2)	AP3642A (pt)
AU (1)	AU2007226430B2 (pt)
BR (1)	BRPI0708708A2 (pt)
CA (1)	CA2645342A1 (pt)
DK (2)	DK2004676T3 (pt)
EA (1)	EA019733B1 (pt)
ES (2)	ES2616341T3 (pt)
IL (2)	IL193965A0 (pt)
MX (1)	MX2008011520A (pt)
NO (1)	NO20083576L (pt)
NZ (1)	NZ570708A (pt)
PL (1)	PL2392587T3 (pt)
SG (1)	SG170092A1 (pt)
UA (1)	UA97800C2 (pt)
WO (1)	WO2007104932A2 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2620446A1 (en)	2012-01-27	2013-07-31	Laboratorios Del Dr. Esteve, S.A.	Immunogens for HIV vaccination
EP3077417A1 (en)	2013-12-08	2016-10-12	Peptcell Limited	Hiv antigens and antibodies and compositions, methods and uses thereof
TWI810456B (zh)	2019-05-22	2023-08-01	美商基利科學股份有限公司	Tlr7調節化合物及hiv疫苗之組合
AU2020384323A1 (en)	2019-11-14	2022-06-02	Aelix Therapeutics, S.L.	Dosage regimens for vaccines

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0330359A3 (en)	1988-02-25	1991-06-05	Bio-Rad Laboratories, Inc.	Composition useful in the diagnosis and treating of hiv-1 infection
DE4141970C2 (de)	1991-12-16	1998-02-19	Charite Med Fakultaet	Kombinationsimpfstoff gegen AIDS, Bilharziose und Tuberkulose und Verfahren zu seiner Herstellung
JPH08504837A (ja)	1993-10-14	1996-05-28	生化学工業株式会社	新規ポリペプチドおよびこれから調製される抗ｈｉｖ剤
EP0728764A4 (en)	1993-10-19	1999-01-20	Ajinomoto Kk	PEPTIDE THE IMMUNE RESPONSE TO HIV UNDUCED AND MEDICINAL PRODUCTS CONTAINING THE PREVENTION OR TREATMENT OF AIDS
US5843724A (en) *	1995-04-27	1998-12-01	Rutgers University	Chimeric nucleic acids and proteins for inhibiting HIV-1 expression
EP0980388A1 (en) *	1997-05-20	2000-02-23	YISSUM RESEARCH DEVELOPMENT COMPANY of the Hebrew University of Jerusalem	Vif-derived hiv protease inhibitors
ES2389519T3 (es)	1997-09-18	2012-10-26	The Trustees Of The University Of Pennsylvania	Casetes de inmunización de ADN de vif atenuados para vacunas genéticas
US6228128B1 (en)	1997-11-10	2001-05-08	Charlotte Johansen	Antimicrobial activity of laccases
US20030180314A1 (en)	1998-07-10	2003-09-25	Degroot Anne	Immunogenic, cross-clade, HIV peptides
US20020182222A1 (en) *	1998-07-10	2002-12-05	Groot Anne De	HIV vaccine candidate peptides
WO2000049038A2 (de) *	1999-02-19	2000-08-24	Ulrich Schubert	Synthetische peptide des regulatorischen virusproteins r (vpr) des humanen immundefizienzvirus typ 1 (hiv-1) und ihre verwendung
NO311807B1 (no)	1999-03-04	2002-01-28	Bionor Immuno As	HIV-peptider, antigener, vaksinepreparater, immunoassay- testsett og en metode for påvisning av antistoffer fremkalt av HIV
WO2001024810A1 (en) *	1999-10-05	2001-04-12	Epimmune Inc.	Inducing cellular immune responses to human immunodeficiency virus-1 using peptide and nucleic acid compositions
WO2001055177A2 (en)	2000-01-28	2001-08-02	Statens Serum Institut	Methods to identify ctl epitopes of hiv
NO314587B1 (no)	2000-09-04	2003-04-14	Bionor Immuno As	HIV regulatoriske- og hjelpepeptider, antigener, vaksinepreparater, immunoassay testsett og en metode for påvisning av antistoffer fremkaltav HIV
AU2002211490A1 (en) *	2000-10-04	2002-04-15	The Trustees Of The University Of Pennsylvania	Compositions and methods of using capsid protein from flaviviruses and pestiviruses
EP1490396A4 (en)	2001-03-01	2006-04-19	Us Gov Health & Human Serv	IMMUNOGENIC HIV PEPTIDES AS REAGENTS AND AS VACCINES
AU2002331599A1 (en) *	2001-08-16	2003-03-03	The General Hospital Corporation	Epitopes of human immunodeficiency virus-1
RU2214274C2 (ru)	2001-08-16	2003-10-20	Государственное предприятие Институт иммунологии Федерального управления медико-биологических экстремальных проблем при МЗ РФ	Иммуногенная композиция, содержащая химерный полипептид вич, полипептиды и тест-система для обнаружения антител к вич
CA2357906A1 (en)	2001-09-28	2003-03-28	Institut Pasteur	Identification of new cd8 epitopes from hiv-1 proteins with therapeutical and vaccinal properties against hiv infections
AU2003299134A1 (en)	2002-05-20	2004-04-23	The General Hospital Corporation	Cytotoxic t-cell epitopes of hiv-1 virus
CA2500715A1 (en)	2002-10-03	2004-04-15	Epimmune Inc.	Hla binding peptides and their uses
US20070054262A1 (en) *	2003-03-28	2007-03-08	Baker Denise M	Methods of identifying optimal variants of peptide epitopes
BRPI0414443A (pt) *	2003-09-17	2006-11-21	Univ Duke	imunógenos consensuais/ancestrais
BRPI0514447B8 (pt) *	2004-08-17	2021-05-25	Centre Nat Rech Scient	uso da função imunosupressora de uma proteína acessória do vírus da imunodeficiência humana ou do símio para a preparação de uma vacina
CN101969996A (zh)	2005-08-23	2011-02-09	加利福尼亚大学董事会	多价疫苗

2007
- 2007-03-09 ES ES07705325.4T patent/ES2616341T3/es active Active
- 2007-03-09 CN CN201110312512.8A patent/CN102443052B/zh not_active Expired - Fee Related
- 2007-03-09 EP EP11167363.8A patent/EP2392587B1/en active Active
- 2007-03-09 US US12/282,132 patent/US20100055119A1/en not_active Abandoned
- 2007-03-09 NZ NZ570708A patent/NZ570708A/xx not_active IP Right Cessation
- 2007-03-09 EP EP07705325.4A patent/EP2004676B1/en active Active
- 2007-03-09 PL PL11167363T patent/PL2392587T3/pl unknown
- 2007-03-09 JP JP2008558877A patent/JP2009529570A/ja active Pending
- 2007-03-09 UA UAA200811993A patent/UA97800C2/uk unknown
- 2007-03-09 CN CN201410764104.XA patent/CN104558126B/zh not_active Expired - Fee Related
- 2007-03-09 DK DK07705325.4T patent/DK2004676T3/en active
- 2007-03-09 EA EA200870342A patent/EA019733B1/ru not_active IP Right Cessation
- 2007-03-09 BR BRPI0708708-0A patent/BRPI0708708A2/pt not_active Application Discontinuation
- 2007-03-09 MX MX2008011520A patent/MX2008011520A/es active IP Right Grant
- 2007-03-09 CA CA002645342A patent/CA2645342A1/en not_active Abandoned
- 2007-03-09 DK DK11167363.8T patent/DK2392587T3/en active
- 2007-03-09 AP AP2008004609A patent/AP3642A/xx active
- 2007-03-09 ES ES11167363.8T patent/ES2573105T3/es active Active
- 2007-03-09 AU AU2007226430A patent/AU2007226430B2/en not_active Ceased
- 2007-03-09 WO PCT/GB2007/000812 patent/WO2007104932A2/en not_active Ceased
- 2007-03-09 AP AP2015008680A patent/AP2015008680A0/xx unknown
- 2007-03-09 SG SG201101721-7A patent/SG170092A1/en unknown
- 2007-03-09 KR KR1020087024478A patent/KR20080106467A/ko not_active Ceased
2008
- 2008-08-18 NO NO20083576A patent/NO20083576L/no not_active Application Discontinuation
- 2008-09-08 IL IL193965A patent/IL193965A0/en unknown
2012
- 2012-05-02 IL IL219544A patent/IL219544A0/en unknown
- 2012-06-18 US US13/526,467 patent/US8992934B2/en active Active
- 2012-09-05 JP JP2012194829A patent/JP2013040172A/ja active Pending
2014
- 2014-08-04 JP JP2014158545A patent/JP6422698B2/ja active Active
2015
- 2015-03-12 US US14/656,690 patent/US9675686B2/en active Active
2017
- 2017-05-05 US US15/588,476 patent/US10034933B2/en active Active

Also Published As

Publication number	Publication date
US8992934B2 (en)	2015-03-31
US20170281750A1 (en)	2017-10-05
CN104558126A (zh)	2015-04-29
HK1171027A1 (en)	2013-03-15
CN102443052B (zh)	2014-12-31
CA2645342A1 (en)	2007-09-20
EA019733B1 (ru)	2014-05-30
DK2392587T3 (en)	2016-05-23
IL219544A0 (en)	2012-06-28
JP2015007069A (ja)	2015-01-15
US20130039937A1 (en)	2013-02-14
IL193965A0 (en)	2011-08-01
KR20080106467A (ko)	2008-12-05
NZ570708A (en)	2011-12-22
JP2013040172A (ja)	2013-02-28
US9675686B2 (en)	2017-06-13
AU2007226430A1 (en)	2007-09-20
CN102443052A (zh)	2012-05-09
CN104558126B (zh)	2020-02-14
WO2007104932A2 (en)	2007-09-20
EP2004676A2 (en)	2008-12-24
AU2007226430A2 (en)	2008-10-09
ES2573105T3 (es)	2016-06-06
SG170092A1 (en)	2011-04-29
MX2008011520A (es)	2009-01-07
DK2004676T3 (en)	2017-02-20
UA97800C2 (uk)	2012-03-26
EP2392587A1 (en)	2011-12-07
EA200870342A1 (ru)	2009-02-27
EP2004676B1 (en)	2016-11-16
US10034933B2 (en)	2018-07-31
JP2009529570A (ja)	2009-08-20
EP2392587B1 (en)	2016-05-04
WO2007104932A3 (en)	2007-11-22
US20150182618A1 (en)	2015-07-02
US20100055119A1 (en)	2010-03-04
AU2007226430B2 (en)	2013-08-29
JP6422698B2 (ja)	2018-11-14
AP2008004609A0 (en)	2008-10-31
AP2015008680A0 (en)	2015-08-31
AP3642A (en)	2016-03-16
PL2392587T3 (pl)	2016-08-31
ES2616341T3 (es)	2017-06-12
BRPI0708708A2 (pt)	2011-06-07

Legal Events

Date	Code	Title	Description
2012-10-22	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20083416L (no)	2008-11-07	Peptidsekvenser og preparater
MX2024012403A (es)	2024-11-08	Novedoso vector del subtipo f del virus adenoasociado (aav) y usos de este
AR064642A1 (es)	2009-04-15	Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
EP4491739A3 (en)	2025-03-26	Method for modifying the resistance profile of spinacia oleracea to downy mildew
PH12021550030A1 (en)	2021-09-20	Nucleotide sequences encoding peptide antigens of sars-cov-2 virus and use thereof
MX358725B (es)	2018-09-03	Antigenos prostaticos de consenso, molecula de acido nucleico que los codifica y vacuna y usos que los comprenden.
EA201100070A1 (ru)	2011-10-31	Туберкулезный белок rv2386c, композиции и их применения
PE20081723A1 (es)	2008-12-14	Vacuna contra el papilomavirus
NO20082149L (no)	2008-07-16	Hundeinfluensavirus og relaterte sammensetninger og fremgangsmater for bruk
MX2011006846A (es)	2011-09-09	Virus de fiebre porcina clasico recombinante (csfv) comprendiendo una proteina e2 modificada y metodos para generar dicho csfv.
NO20083576L (no)	2008-12-10	Peptider av regulatoriske eller hjelpeproteiner av HIV, samt sammensetninger og anvendelser derav
BRPI0715331B8 (pt)	2021-05-25	polipeptídeo que compreende uma porção n-terminal e uma porção c-terminal, e uso do mesmo
BR0309491A (pt)	2005-02-15	Composição de vacina, composição imunogênica, utilização de uma proteìna e7 e anticorpos neutralizantes
DE602005018615D1 (de)	2010-02-11	Schen polypeptiden und deren verwendung als impfstoffe und in der immuntherapie
RU2009115688A (ru)	2010-11-10	Иммуногенные гибридные полипептиды против ожирения и композиция вакцин против ожирения, содержащая эти полипептиды
WO2007127290A3 (en)	2008-08-07	Method for producing viral vaccine and therapeutic peptide antigens
NO20084348L (no)	2008-12-23	Vaksine for terapeutiske eller profylaktisk behandling av myastenia gravis
BRPI0508916A (pt)	2007-08-14	polipeptìdeos hìbridos imunogênicos antiobesidade e composição de vacina antiobesidade compreendendo-os
NO20085201L (no)	2009-03-05	Rekombinante novirhabdoviruser og deres anvendelse
ATE466876T1 (de)	2010-05-15	Immunogene konstrukte
BR0012556A (pt)	2002-07-02	Genes e vacinas de ehrlichia canis
BR112013009276A2 (pt)	2019-09-24	peptídeos de c18orf54 e vacinas incluindo os mesmos
WO2020144355A3 (fr)	2020-09-03	Peptides immunogènes issus de la nucléoprotéine du virus ebola zaïre
UA100496C2 (ru)	2013-01-10	Последовательность пептида, который является иммуногенным для позвоночного, и композиция
NO20082810L (no)	2008-08-12	Vaksine, og anvendelse av samme